Authored By: B. V Waghmare

Sunday, September 7, 2014

Protein that protect from TB infection developing in to lung infection

Biomarker that will help predict if a person will develop fetal lung disease associated with TB infection and can be used to treat Mycobacterium tuberculosis infection.

Every individual who encounter Mycobacterium tuberculosis infection do not develop an active form of TB, such individuals may test positive for Mycobacterium tuberculosis infection or antibody test.

A protein interleukin-32 is found in such individuals which protect them from developing TB infection into an active form of TB or fetal lung disease. Interleukin-32 help immune cells of body to kill Mycobacterium tuberculosis bacteria in presence of Vitamin D. Vitamin D is very important for protecting individual from developing active form of TB, in presence of Vitamin D protein interleukin-32 induce killing of Mycobacterium tuberculosis.

Presences of biomarker interleukin-32 in patients with latent TB can be used to predict if such patients will develop active form of TB or never. Synthetic Interleukin-32 can be used to develop pharmaceutical substance to treat TB patients with deficiency of interleukin-32 as well.

Source :

Last updated: 07-Sep -2014

B V Waghmare (2014). Interlukin 32 biomarker that will predict relapse of tuberculosis infection and will be used in treatment of TB

Tuesday, September 2, 2014

HIV neutralising antibodies for passive immunization.

Advanced treatment of HIV infection with HIV neutralizing antibodies under development.

Anti retroviral drugs must not be discontinued so as to keep HIV viral load under control to maintain quality of life, still many patients discontinue taking drugs for many reasons like anti retroviral drugs have their own set of side effects and complications, availability.
Now such patients have better option as scientists from National Institute of Health United States of America have developed broadly active antibodies against HIV, which are tested in patients who have discontinued their medicines and were able to lower viral loads, in laboratory study it is proven that new CD4 cells were not infected by HIV virus in presence of these antibodies incubated for sufficient time.
These antibodies are Broadly neutralizing antibodies (bNAbs) which are called as PGT121, VRC01 and VRC03. These antibodies can be used for immunization for patients and healthcare personals at high risk. Combination of these antibodies along with HAART will help in reducing drug load and their side effects after prolonged use.


Last updated: 02-Sep-2014

Authored By : B V Waghmare